RESEARCH TRIANGLE PARK – John Bailey, a veteran pharmaceutical industry executive, will take over as CEO effective Jan. 1 at G1 Therapeutics as part of a leadership transition plan, the RTP-based firm announced Thursday.
Bailey already is a member of the G1 board. He most recently served as the president of GSK’s pharmaceuticals and vaccines in the US.
Mark Velleca, the current CEO, will remain on the board and serve as a senior advisor. He has led the company since 2014.
“Mr. Bailey has nearly thirty years of commercial pharmaceutical experience and an in-depth understanding of healthcare market dynamics and the evolution of value-based healthcare systems in the U.S. He has extensive experience successfully guiding the launch and growth of multiple pharmaceutical products,” G1 said.
“Most recently, Mr. Bailey served as President of GlaxoSmithKline’s pharmaceuticals and vaccines business in the U.S., with responsibility for commercialization efforts across the company’s oncology, immunology/rare disease, respiratory and vaccines portfolios. Earlier in his career, he held various senior leadership positions at Eli Lilly and Company. Mr. Bailey was appointed to the G1 Board of Directors in March 2020. He also serves on the board of Emergo Therapeutics and is a past member of the Board of Directors of PhRMA, the pharmaceutical industry trade association, and the North Carolina Biotechnology Center.”
